# A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

Source: https://onco.cc/trials/nct05443126/  
OnCo record `nct05443126` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EP0031 and Pemetrexed in non-small-cell lung cancer, run by Ellipses Pharma, now recruiting.

## Summary

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies is a phase 1/2 interventional study registered as NCT05443126 by Ellipses Pharma, with 265 participants planned, started 2022-09-30 and due to reach its primary completion in 2027-03. Interventions recorded: EP0031, Platinum chemotherapy and Pemetrexed.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05443126
- Phase: 1/2
- Setting: A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies
- Sponsor: Ellipses Pharma
- Enrolled: 265

## Sources

- ClinicalTrials.gov NCT05443126: https://clinicaltrials.gov/study/NCT05443126

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [EP0031](https://onco.cc/drugs/ep0031/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05443126.json